8 results on '"Pitta ID"'
Search Results
2. Synthesis and biological evaluation of novel imidazolidine derivatives as candidates to schistosomicidal agents.
- Author
-
Matos-Rocha TJ, Lima MD, Silva AL, Oliveira JF, Gouveia AL, Silva VB, Almeida AS Júnior, Brayner FA, Cardoso PR, Pitta-Galdino MD, Pitta ID, Rêgo MJ, Alves LC, and Pitta MG
- Subjects
- Animals, Humans, Imidazolidines chemical synthesis, Imidazolidines toxicity, Mice, Microscopy, Electron, Scanning, Parasitic Sensitivity Tests, Schistosoma mansoni ultrastructure, Schistosomicides chemical synthesis, Schistosomicides toxicity, Time Factors, Imidazolidines pharmacology, Peripheral Blood Stem Cells drug effects, Schistosoma mansoni drug effects, Schistosomicides pharmacology
- Abstract
Introduction:: Schistosomiasis is an infectious parasitic disease caused by trematodes of the genus Schistosoma, which threatens at least 258 million people worldwide and its control is dependent on a single drug, praziquantel. The aim of this study was to evaluate the anti-Schistosoma mansoni activity in vitro of novel imidazolidine derivatives., Material and Methods:: We synthesized two novel imidazolidine derivatives: (LPSF/PTS10) (Z)-1-(2-chloro-6-fluorobenzyl)-4-(4-dimethylaminobenzylidene)-5-thioxoimidazolidin-2-one and (LPSF/PTS23) (Z)-1-(2-chloro-6-fluoro-benzyl)-5-thioxo-4-(2,4,6-trimethoxy-benzylidene)-imidazolidin-2-one. The structures of two compounds were determined by spectroscopic methods. During the biological assays, parameters such as motility, oviposition, mortality and analysis by Scanning Electron Microscopy were performed., Results:: LPSF/PTS10 and LPSF/PTS23 were considered to be active in the separation of coupled pairs, mortality and to decrease the motor activity. In addition, LPSF/PTS23 induced ultrastructural alterations in worms, after 24 h of contact, causing extensive erosion over the entire body of the worms., Conclusion:: The imidazolidine derivatives containing the trimetoxy and benzylidene halogens showed promising in vitro schistosomicidal activity.
- Published
- 2017
- Full Text
- View/download PDF
3. Evaluation of Antibacterial, Antineoplastic, and Immunomodulatory Activity of Paullinia cupana Seeds Crude Extract and Ethyl-Acetate Fraction.
- Author
-
Carvalho LV, Cordeiro MF, E Lins TU, Sampaio MC, de Mello GS, da Costa VC, Marques LL, Klein T, de Mello JC, Cavalcanti IM, Pitta ID, Galdino da Rocha Pitta M, and Rêgo MJ
- Abstract
Paullinia cupana (Guarana) is a native plant of Amazon region that has very traditional importance. Its seeds are rich in bioactive compounds, including tannins, which exhibit relevant properties. Objective. This study aimed to evaluate antibacterial, antineoplastic, and immunomodulatory activity of P. cupana seeds crude extract (CE) and ethyl-acetate fraction (EAF). Methods. Antibacterial activity was evaluated by determination of minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC). Antineoplastic activity was evaluated by MTT assays in hepatocellular carcinoma (HepG2), breast adenocarcinoma (MCF-7), ductal carcinoma (T47-D), non-Hodgkin's B cell lymphoma (Toledo), T cell leukemia (Jukart), and Acute Leukemia (HL-60) cell lines. BALB/c mice splenocytes were treated to assess IFN- γ , IL-6, IL-17, and IL-10 levels by sandwich ELISA. Results. CE and EAF were not toxic to peripheral blood cells and splenocytes. CE and EAF fractions showed a bacteriostatic activity (MIC = 250 μ g/mL) and presented IC
50 values of 70.25 μ g/mL and 61.18 μ g/mL in HL-60 leukemia cell line. All cytokines evaluated had their levels reduced after treatment, following dose-response model. Discussion and Conclusion. Different biological activities were observed for both CE and EAF, suggesting P. cupana as a source of bioactive substances, especially tannins that may be used for several diseases treatments., Competing Interests: The authors report no declarations of interests.- Published
- 2016
- Full Text
- View/download PDF
4. Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity.
- Author
-
de Oliveira PS, Pereira MC, Silva de Paula SK, Lima EV, Lima MM, de Arruda RG, de Oliveira WL, Duarte ÂL, Pitta ID, Rêgo MJ, and Galdino da Rocha Pitta M
- Subjects
- Adult, Aged, Brazil, Cohort Studies, Comorbidity, Cytokines metabolism, Dermatology, Female, Humans, Male, Middle Aged, Psoriasis drug therapy, Skin metabolism, Skin pathology, Th1 Cells metabolism, Th17 Cells metabolism, Young Adult, Forkhead Transcription Factors metabolism, Interferon-gamma metabolism, Interleukin-17 metabolism, Psoriasis metabolism
- Abstract
Psoriasis is a chronic and recurrent dermatitis, mediated by keratinocytes and T cells. Several proinflammatory cytokines contribute to formation and maintenance of psoriatic plaque. The Th1/Th17 pathways and some of IL-1 family members were involved in psoriasis pathogenesis and could contribute to disease activity. Therefore, we sought to analyse skin transcript levels of IL17A, IL22, RORC, IL8, IFNG, IL33, IL36A, FOXP3, and IL10 and correlate with clinic of patients with plaque-type psoriasis. In order to conduct that, we collected punch biopsies from lesional skin and obtained tissue RNA. After reverse transcription, qRT-PCR quantified the relative mRNA expression. The main results revealed increased transcripts levels of IL17A, IFNG, and FOXP3 in moderate-severe patients. Despite this, only IL17A can increase the chance to worsen disease severity. We also observed many significant positive correlations between each transcript. In conclusion, IL17A is elevated in lesional skin from psoriasis patients and plays crucial role in disease severity., Competing Interests: All authors declare no conflict of interests.
- Published
- 2016
- Full Text
- View/download PDF
5. Reassessing the Role of the Active TGF- β 1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.
- Author
-
Dantas AT, Gonçalves SM, de Almeida AR, Gonçalves RS, Sampaio MC, Vilar KM, Pereira MC, Rêgo MJ, Pitta ID, Marques CD, Duarte AL, and Pitta MG
- Subjects
- Adult, Aged, Biopsy, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Scleroderma, Systemic blood, Scleroderma, Systemic genetics, Young Adult, Biomarkers analysis, Leukocytes, Mononuclear metabolism, Scleroderma, Systemic diagnosis, Skin metabolism, Transforming Growth Factor beta1 blood, Transforming Growth Factor beta1 genetics
- Abstract
Objective . To determine active TGF- β 1 (aTGF- β 1) levels in serum, skin, and peripheral blood mononuclear cell (PBMC) culture supernatants and to understand their associations with clinical parameters in systemic sclerosis (SSc) patients. Methods . We evaluated serum samples from 56 SSc patients and 24 healthy controls (HC). In 20 SSc patients, we quantified spontaneous or anti-CD3/CD28 stimulated production of aTGF- β 1 by PBMC. The aTGF- β 1 levels were measured by ELISA. Skin biopsies were obtained from 13 SSc patients and six HC, and TGFB1 expression was analyzed by RT-PCR. Results . TGF- β 1 serum levels were significantly higher in SSc patients than in HC ( p < 0.0001). Patients with increased TGF- β 1 serum levels were more likely to have diffuse subset ( p = 0.02), digital ulcers ( p = 0.02), lung fibrosis ( p < 0.0001), positive antitopoisomerase I ( p = 0.03), and higher modified Rodnan score ( p = 0.046). Most of our culture supernatant samples had undetectable levels of TGF- β 1. No significant difference in TGFB1 expression was observed in the SSc skin compared with HC skin. Conclusion . Raised active TGF- β 1 serum levels and their association with clinical manifestations in scleroderma patients suggest that this cytokine could be a marker of fibrotic and vascular involvement in SSc., Competing Interests: The authors report no declarations of interest.
- Published
- 2016
- Full Text
- View/download PDF
6. UHPLC Quantitation Method for New Thiazolidinedione LPSF/GQ-02 and In Vitro/In Vivo Kinetic Studies.
- Author
-
Vieira CM, Campos ML, Padilha EC, Pitta M, Pitta ID, de Lima MD, and Peccinini RG
- Subjects
- Administration, Intravenous, Animals, Half-Life, Humans, Hydrogen-Ion Concentration, Male, Rats, Rats, Wistar, Thiazolidinediones toxicity, Tissue Distribution, Chromatography, High Pressure Liquid methods, Kidney metabolism, Liver metabolism, Thiazolidinediones pharmacokinetics
- Abstract
Background: LPSF/GQ-02 is a promising benzylidene thiazolidinedione that has demonstrated antidiabetic, antidyslipidemic, anti-atherosclerotic properties and can also treat non-alcoholic fatty liver disease. Despite all activity studies of the new compound, its pharmacokinetics are not yet described., Objective: The aim of this study was to perform its first pharmacokinetic profile., Methods: For this purpose a bioanalytical method for the quantitation of 5-(4- Chloro-benzylidene)-3-(4-methylbenzyl)-thiazolidine-2,4-dione (LPSF/GQ-02) was developed and validated. A Waters UPLC chromatographer using a BEH column (2.1x50mm, 1.7μm particle), mobile phase water:acetonitrile (20:80) was used. The range of calibration curve in plasma was 1.9 to 250 ng/mL with r = 0.9997. LPSF/GQ-02 stability was evaluated in rat plasma and buffers at pH 1.2 and 7.4. The pharmacokinetic assay was carried out in male Wistar rats weighing 250-300 g. The animals received LPSF/GQ-02 at 3 mg/kg by intravenous route. The animals were used to perform a preliminary safety study concerning the evaluation of liver and kidney biomarkers (ALT, AST, urea, creatinine)., Results: The obtained pharmacokinetic parameters were elimination half-life of 4.44 h, Cl of 8.00 L/h.kg, Vd of 45.60 L/kg and MRT of 3.79h. No difference was observed for the liver and kidney biomarkers., Conclusion: The intravenous pharmacokinetic parameters are in agreement with a good future posology, even though the plasma concentrations from oral administration were not quantifiable in a dose of 12 mg/kg. The preliminary safety study demonstrated no acute effect of the drug in liver and kidneys. The LPSF/GQ-02 is a new thiazolidinedione that should continue being evaluated for future clinical use.
- Published
- 2016
- Full Text
- View/download PDF
7. Pre-clinical pharmacokinetics of the acridine antitumour candidate AC04 and its 1-oxo-metabolite plasma profile.
- Author
-
Pigatto MC, Uchôa Fde T, Torres B, Haas S, do Carmo Alves de Lima M, Galdino SL, Rocha Pitta Id, Peporine Lopes N, and Dalla Costa T
- Subjects
- Acridines therapeutic use, Animals, Area Under Curve, Chromatography, High Pressure Liquid, Chromatography, Liquid, Male, Neoplasms drug therapy, Rats, Thiazolidinediones blood, Thiazolidinediones therapeutic use, Tissue Distribution, Acridines pharmacokinetics, Antineoplastic Agents pharmacokinetics, Thiazolidinediones pharmacokinetics
- Abstract
This work aimed to investigate plasma pharmacokinetics and tissue distribution of a new acridine derivative 5-acridin-9-ylmethylene-3-(4-methyl-benzyl)-thiazolidine-2,4-dione (AC04) and its 1-oxo-AC04 metabolite disposition in Wistar rats. After a single AC04 1.5 mg/kg intravenous (i.v.) bolus dose, blood samples were taken up to 120 h. Plasma samples were deproteinization, and AC04 and metabolite were quantified by validated liquid chromatography in tandem with mass spectrometry method. Protein binding was determined by ultrafiltration. AC04 tissue disposition was evaluated after i.v. bolus dose. Individual AC04 concentration-time profiles were best fitted by a two-compartment model showing CL(tot) of 3.4 ± 3.4 L/h/kg, Vd(SS) of 137.9 ± 91.4 L/kg, AUC(0-∞) of 788 ± 483 ng·h/mL and a t(1/2) of 45.5 ± 31.5 h. Protein binding was 98.1 ± 1.6%. AC04 showed higher penetration into the lung, spleen and liver, with AUC(0-96) of 798,443, 263,211 and 303,722 ng·h/mL, respectively. The 1-oxo-AC04 metabolite represented 10% of AC04 plasma concentration, showing a t(1/2) of 23.2 ± 10.4 h. These results suggest that, despite the small free plasma fraction, AC04 penetrates extensively reaching high concentrations in most tissues residing for a long time, which is important for its activity on solid tumours. All results combined indicate that AC04 is potentially a good antitumour candidate.
- Published
- 2012
- Full Text
- View/download PDF
8. [Synthesis and antifungal activity of chlorobenzyl benzylidene thiazolidinediones and substituted of imidazolidinediones].
- Author
-
Goes AJ, De Lima MC, Galdino SL, Pitta ID, and Luu-Duc C
- Subjects
- Antifungal Agents chemical synthesis, Antifungal Agents pharmacology, In Vitro Techniques, Candida albicans drug effects, Escherichia coli drug effects, Neurospora crassa drug effects, Staphylococcus aureus drug effects
- Abstract
The synthesis of six benzylidene thiazolidinediones and four benzylidene imidazolidinediones is described. In order to investigate their antifungal activity, they are evaluated against microorganism such as Candida albicans, Neurospora crassa, Staphylococcus aureus and Escherichia coli.
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.